Novocure (NVCR) Tops Q3 EPS by 7c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Novocure (NVCR) Tops Q3 EPS by 7c, Revenues Beat

Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

October 31, 2019 6:00 AM EDT

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018

First quarter ever of positive net income with $0.02 in earnings per share

Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next five years

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2019, highlighting strengthening financial performance, multiple levers to drive near-term growth and building momentum for the Tumor Treating Fields platform. Novocure is... More